224 results on '"Navasa M"'
Search Results
2. GS5/26 REGULATION OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) BY ENDOTOXIN AND CYTOKINES
3. C11/198 LIVER TRANSPLANTATION (OLT) FOR HEPATOCELLULAR CARCINOMA (HCC)
4. Hepatopulmonary syndrome in candidates for liver transplantation
5. DAA therapy improves early post-liver transplant survival and induces significant changes in wait-list composition
6. Survival benefit of liver transplantation in Catalonia: A 2007–13 analysis
7. Prevalence of subclinical histological lesions and tolerance biomarkers in long-term adult liver transplant recipients considered for immunosuppression withdrawal
8. Long-term subclinical inflammatory lessions in liver transplant recipients
9. Donor mannose-binding lectingene polymorphisms increase the risk of severe bacterial infections after liver transplantation
10. Impact of sustained virologic response on liver fibrosis in recurrent hepatitis C after liver transplantation
11. MiRNA 181a and 148a plasma levels during acute cellular rejection in liver transplantation
12. Noninvasive assessment of liver fibrosis and portal hypertension after viral eradication in post-transplant hepatitis C
13. Hepatic Encephalopathy is an Independent Risk Factor for Transplant-Free Survival in Patients Awaiting Liver Transplantation
14. FRI-038 - Long-term subclinical inflammatory lessions in liver transplant recipients
15. FRI-037 - DAA therapy improves early post-liver transplant survival and induces significant changes in wait-list composition
16. PS-047 - Prevalence of subclinical histological lesions and tolerance biomarkers in long-term adult liver transplant recipients considered for immunosuppression withdrawal
17. P0704 : Deep-sequencing analysis demonstrates the persistence of the pre-transplant HCV dominant variant within a more homogeneous quasispecies after liver transplantation in cholestatic hepatitis C patients
18. P1185 INTERIM SVR12 RESULTS FROM THE TELAPREVIR PHASE 3B REPLACE STUDY IN TREATMENT-NAIVE STABLE LIVER TRANSPLANT PATIENTS WITH GENOTYPE 1 HCV INFECTION
19. P10 INTERFERON LAMBDA 4 (IFNL4) POLYMORPHISM PREDICTS RESPONSE TO HEPATITIS C TREATMENT AFTER LIVER TRANSPLANTATION
20. P888 USEFULNESS OF ELF, IP10, FIBROSCAN AND THEIR COMBINATIONS IN THE EARLY PREDICTION OF SEVERE HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION
21. P1008 A 5.9 kDa SERUM FRAGMENT OF FIBRINOGEN a-CHAIN IS A SPECIFIC SURROGATE MARKER OF ACTIVE FIBROGENESIS IN PATIENTS WITH LIVER DISEASE
22. O39 LONG TERM OUTCOME OF MILD HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: A LARGE PROSPECTIVE STUDY
23. P1186 TREATMENT-NAIVE STABLE LIVER TRANSPLANT PATIENTS WITH GENOTYPE-1 HCV INFECTION: PHARMACOKINETIC RESULTS OF ADJUSTED DOSING WITH TACROLIMUS OR CYCLOSPORINE IN THE TELAPREVIR REPLACE STUDY
24. THU-013 - Hepatic Encephalopathy is an Independent Risk Factor for Transplant-Free Survival in Patients Awaiting Liver Transplantation
25. 156 HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: MAINTENANCE THERAPY WITH PEGYLATED INTERFERON IN NONRESPONDERS TO STANDARD THERAPY SLOWS THE DISEASE PROGRESSION AND IMPROVES SURVIVAL
26. 155 EFFICACY AND SAFETY OF STANDARD ANTIVIRAL THERAPY IN CIRRHOTIC PATIENTS AWAITING LIVER TRANSPLANTATION (LT)
27. 180 EVEROLIMUS-BASED IMMUNOSUPPRESSION IN HCV POSITIVE DE NOVO LIVER TRANSPLANT RECIPIENTS: 24-MONTH RESULTS OF A RANDOMIZED CONTROLLED TRIAL
28. 558 HCV KINETICS DURING AND AFTER THE ANHEPATIC PHASE: IS THE LIVER THE PRIMARY SITE FOR HCV CLEARANCE?
29. 808 MODELING HCV KINETICS DURING INTRAVENOUS SILIBININ MONOTHERAPY IN THE PERI-TRANSPLANT PERIOD
30. 147 HEPATIC ENCEPHALOPATHY IS AN INDEPENDENT RISK FACTOR FOR MORTALITY IN PATIENTS AWAITING LIVER TRANSPLANTATION
31. 169 EARLY EVALUATION OF HISTOLOGICAL MARKERS OF FIBROSIS AND CELLULAR PROLIFERATION IN LIVER TRANSPLANT PATIENTS WITH HCV RECURRENCE
32. 186 AN INCREASED LIVER STIFFNESS MEASUREMENT ONE YEAR AFTER TRANSPLANTATION IS VERY ACCURATE AT PREDICTING CLINICAL OUTCOMES IN HEPATITIS C RECURRENCE
33. 207 PERIPORTAL SINUSOIDAL FIBROSIS IS AN EARLY MARKER OF PORTAL HYPERTENSION AND SIGNIFICANT FIBROSIS IN HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION
34. 183 SINGLE OPERATOR PERORAL CHOLANGIOSCOPY IN LIVER TRANSPLANT RECIPIENTS REQUIRING EVALUATION OF THE BILIARY TRACT
35. 187 ANTIVIRAL THERAPY IN RECURRENT HEPATITIS C: ADVANCED DONOR AGE AND FEMALE RECIPIENT GENDER IDENTIFY NON RESPONDERS AT HIGHER RISK OF GRAFT LOSS
36. 849 INTERPLAY BETWEEN BASIC RESIDUES OF HEPATITIS C VIRUS GLYCOPROTEIN E2 WITH LIPOPROTEINS, VIRAL RECEPTORS AND NEUTRALIZING ANTIBODIES
37. 30 A COMBINATION OF BASELINE VARIABLES INCLUDING IL28B POLYMORPHISM CAN ACCURATELY PREDICT RESPONSE TO ANTIVIRAL TREATMENT IN HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION
38. 554 PREVALENCE OF HISTOLOGICAL LESIONS IN LONG-TERM BIOPSIES AFTER LIVER TRANSPLANTATION
39. 781 IDENTIFICATION OF HEPATITIS C VIRUS (HCV) GLYCOPROTEIN E2 DOMAINS AND RESIDUES RESPONSIBLE FOR INTERACTION WITH HEPARAN SULFATE
40. 647 LIVER TRANSPLANTATION FOR INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) AND COMBINED HEPATOCELLULAR-CHOLANGIOCARCINOMA(CHCC-CC)
41. 798 CELL CULTURE REPLICATION OF A GENOTYPE 1B HEPATITIS C VIRUS ISOLATE CLONED FROM A PATIENT WHO UNDERWENT LIVER TRANSPLANTATION
42. 531 EARLY IDENTIFICATION OF TWO PATTERNS OF HEPATITIS C RECURRENCE (RAPID AND SLOW PROGRESSORS) AFTER LIVER TRANSPLANTATION: A PROSPECTIVE LONG-TERM FOLLOW-UP STUDY
43. 534 BACTERIAL LIPOPOLYSACCHARIDE (LPS) INHIBITS CB2 RECEPTOR EXPRESSION IN HUMAN MONOCYTIC CELLS
44. 24 HIGHER SUSTAINED VIROLOGIC RESPONSE AND HISTOLOGIC IMPROVEMENT IN RECURRENT HEPATITIS C AFTER PEGYLATED INTERFERON PLUS RIBAVIRIN THERAPY UNDER CYCLOSPORINE-BASED VERSUS TACROLIMUS-BASED IMMUNOSUPPRESSIVE THERAPY
45. 451 CLINICAL, HISTOLOGICAL AND HEMODINAMIC OUTCOMES IN HCV-INFECTED LIVER TRANSPLANT RECIPIENTS TREATED WITH PEGILATED INTERFERON PLUS RIBAVIRIN
46. 6 CURRENT EFFICACY OF RECOMMENDED EMPIRICAL ANTIBIOTIC THERAPY IN PATIENTS WITH CIRRHOSIS AND BACTERIAL INFECTION
47. 100 TRANSLOCATION OF BACTERIAL DNA IS ASSOCIATED WITH WORSENING OF THE HYPERKINETIC SYSTEMIC CIRCULATION AND OF INTRA-HEPATIC ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CIRRHOTIC AND ASCITES
48. 450 SERUM MARKERS OF LIVER FIBROSIS IDENTIFY PATIENTS WITH MILD AND SEVERE HEPATITIS C RECURRENCE DURING THE FIRST MONTHS AFTER LIVER TRANSPLANTATION
49. 449 COMPLICATIONS AFTER ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP) IN LIVER TRANSPLANT (LT) RECIPIENTS
50. 174 RISK FACTORS AND CLINICAL INFLUENCE OF EARLY CALCINEURIN INHIBITOR-INDUCED NEUROTOXICITY IN LIVER TRANSPLANTATION
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.